Related Experiment Video
Updated: Jan 22, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Squamous cell lung cancer: genomic evolution and personalized therapy
Andrés F Cardona1,2,3, Luisa Ricaurte2, Zyanya Lucía Zatarain-Barrón4
1Grupo Oncología Clínica y Traslacional, Clínica del Country. Bogotá, Colombia.
Objective:
To review the state-of-the-art in relation to the current information on squamous cell lung cancer (SCLC). We describe the genetic anomalies reported, their effect, and finally the most promising therapeutic agents.
Materials And Methods:
We reviewed published articles in peer-reviewed journals as well as current treatment guidelines from local and international resources.
Results:
SCLC represents a smaller proportion of the global burden of disease for lung cancer compared to its more frequent presentation, the adenocarcinoma. However, more than 400 000 cases are reported annually, a substantial population for whom therapeutic options are scarce and with limited efficacy. Several groups have been given the task of elucidating the mechanisms that lead to the development of SCLC, including molecular anomalies that can be used as targets for drug design.
Conclusions:
There are potential therapeutic targets for SCLC, which must be studied in clinical trials for validation.
Insights
Squamous cell lung cancer (SCLC) affects over 400,000 people annually. Research is identifying molecular targets for new, more effective SCLC therapies.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Squamous cell lung cancer (SCLC) accounts for a significant portion of lung cancer diagnoses, despite being less common than adenocarcinoma.
- Over 400,000 new SCLC cases are reported globally each year, highlighting a critical need for improved treatment options.
Purpose of the Study:
- To provide a comprehensive review of the current knowledge regarding squamous cell lung cancer (SCLC).
- To detail the genetic anomalies associated with SCLC development and their implications.
- To identify and discuss promising therapeutic agents for SCLC treatment.
Main Methods:
- Systematic review of peer-reviewed scientific literature.
- Analysis of current treatment guidelines from national and international health organizations.
Main Results:
- SCLC, while less prevalent than lung adenocarcinoma, affects a substantial patient population worldwide.
- Current therapeutic options for SCLC are limited in efficacy.
- Ongoing research is focused on understanding the molecular underpinnings of SCLC to identify novel drug targets.
Conclusions:
- Emerging molecular targets show promise for SCLC treatment.
- Clinical trials are essential to validate the efficacy of these potential new therapies for squamous cell lung cancer.
Related Concept Videos
03:21Genome Size and the Evolution of New Genes
03:21Genome Size and the Evolution of New Genes
02:02Genomics
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:55The Evidence for Evolution